Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announces that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock (“Common Stock”), plus one non-tradeable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing.
Read the full article: Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right //
Source: https://www.prnewswire.com/news-releases/elevation-oncology-enters-into-agreement-to-be-acquired-by-concentra-biosciences-for-0-36-in-cash-per-share-plus-a-contingent-value-right-302475956.html